N-(3-bromophenethyl)-4-methylbenzenesulfonamide | 494833-87-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-bromophenethyl)-4-methylbenzenesulfonamide
• 英文别名: N-[2-(3-bromophenyl)ethyl]-4-methylbenzenesulfonamide
• CAS: 494833-87-3
• 化学式: C₁₅H₁₆BrNO₂S
• 分子量: 354.268
• InChiKey: DZMWOUKWJUNQIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-bromophenethyl)-4-methylbenzenesulfonamide 在 aluminum (III) chloride 、 氯化亚砜 、 potassium carbonate 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 25.0h， 生成 7-bromo-3-tosyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-one
  参考文献：
  名称：

  BIIB091（一种用于治疗多发性硬化症的可逆选择性 BTK 抑制剂）的发现和临床前表征

  摘要：

  多发性硬化症是一种中枢神经系统 (CNS) 的慢性自身免疫性神经退行性疾病，其特征是炎症、脱髓鞘和轴突损伤，导致永久性残疾。在多发性硬化症的早期阶段，炎症是疾病进展的主要驱动因素。开发具有卓越安全性的高效疗法以预防导致残疾的炎症过程的需求仍然未得到满足。在此，我们描述了 BIIB091 的发现，BIIB091 是一种结构独特的正位 ATP 竞争性可逆抑制剂，在 DFG-in 确认中与 BTK 蛋白结合，旨在将 BTK 上的重要磷酸化位点 Tyr-551 隔离成具有优异亲和力的非活性构象。 。临床前研究表明，BIB091 是一种高效分子，具有良好的类药特性和安全性/耐受性，适合临床开发作为治疗多发性硬化症等自身免疫性疾病的高选择性、可逆性 BTKi。

  DOI：

  10.1021/acs.jmedchem.1c00926
• 作为产物：
  描述：

  对甲苯磺酰氯 在 sodium azide 、 二氢吡啶 、 1,3-dicyano-5-fluoro-2,4,6-tris(diphenylamino)benzene 、 4-甲苯硫酚 作用下， 以 水 、 1,2-二氯乙烷 、 丙酮 为溶剂， 反应 10.0h， 生成 N-(3-bromophenethyl)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  Organo‐Photocatalytic Anti‐Markovnikov Hydroamidation of Alkenes with Sulfonyl Azides: A Combined Experimental and Computational Study

  摘要：

  The construction of C(sp3)−N bonds via direct N‐centered radical addition with olefins under benign conditions is a desirable but challenging strategy. Herein, we describe an organo‐photocatalytic approach to achieve anti‐Markovnikov alkene hydroamidation with sulfonyl azides in a highly efficient manner under transition‐metal‐free and mild conditions. A broad range of substrates, including both activated and unactivated alkenes, are suitable for this protocol, providing a convenient and practical method to construct sulfonylamide derivatives. A synergistic experimental and computational mechanistic study suggests that the additive, Hantzsch ester (HE), might undergo a triplet‐triplet energy transfer manner to achieve photosensitization by the organo‐photocatalyst under visible light irradiation. Next, the resulted triplet excited state 3HE* could lead to a homolytic cleavage of C4−H bond, which triggers a straightforward H‐atom transfer (HAT) style in converting sulfonyl azide to the corresponding key amidyl radical. Subsequently, radical addition of the amidyl radical to alkenes followed by HAT from p‐toluenethiol could proceed to afford the desired anti‐Markovnikov hydroamidation product. It is worth noting that mechanistic pathway bifurcation could be possible for this reaction. A feasible radical chain propagation mechanistic pathway is also proposed to rationalize the high efficiency of this reaction.

  DOI：

  10.1002/anie.202406069

文献信息

• [EN] BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE<br/>[FR] ANALOGUES DE BENZOAZÉPINE UTILISÉS EN TANT QU'AGENTS INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：BIOGEN MA INC

  公开号：WO2018191577A1

  公开（公告）日：2018-10-18

  Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their production and compounds of formula (I) for use in treating a disease responsive to the inhibition of Bruton's tyrosine.

  提供了式（I）的化合物，或其药学上可接受的盐，以及它们的制备方法和用于治疗对布鲁顿酪氨酸抑制敏感的疾病的式（I）的化合物。
• [EN] BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY<br/>[FR] COMPOSÉS BIARYLIQUES UTILES POUR LE TRAITEMENT DE MALADIES HUMAINES EN ONCOLOGIE, NEUROLOGIE ET IMMUNOLOGIE
  申请人：BIOGEN IDEC INC

  公开号：WO2015089337A1

  公开（公告）日：2015-06-18

  The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

  本发明提供了作为布鲁顿酪氨酸激酶抑制剂并具有相同理想特性的化合物及其组合物。
• [EN] SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS DE N-HÉTÉROARYL TÉTRAHYDRO-ISOQUINOLINES SUBSTITUÉES, PROCÉDÉ DE PRÉPARATION ET USAGE THÉRAPEUTIQUE ASSOCIÉS
  申请人：SANOFI SA

  公开号：WO2011143155A1

  公开（公告）日：2011-11-17

  The present invention discloses and claims a series of substituted N-heteroaryl tetrahydro-isoquinoline derivatives of Formula (I). Wherein R, R1, R2, X, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted N-heteroaryl tetrahydro-isoquinoline derivatives of Formula (I) and intermediates therefor.

  本发明公开并声明了一系列Formula (I)的N-杂环芳基四氢异喹啉衍生物。其中R、R1、R2、X、m、n和p如本文所述。更具体地说，本发明的化合物是H3受体调节剂，因此在制药剂中特别有用，特别是在治疗和/或预防多种由H3受体调节的疾病中，包括与中枢神经系统相关的疾病。此外，本发明还公开了制备Formula (I)的N-杂环芳基四氢异喹啉衍生物及其中间体的方法。
• [EN] SUBSTITUTED N-ALKYL AND N-ACYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS N-ALKYL ET N-ACYL TÉTRAHYDRO-ISOQUINOLINE SUBSTITUÉS, PROCÉDÉ DE PRÉPARATION ET APPLICATION THÉRAPEUTIQUES ASSOCIÉS
  申请人：SANOFI SA

  公开号：WO2011143145A1

  公开（公告）日：2011-11-17

  The present invention discloses and claims a series of substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives of formula (I). Wherein R, R1, R2, X, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives of formula (I) and intermediates therefor.

  本发明揭示并声明了一系列式(I)的取代N-烷基和N-酰基四氢异喹啉衍生物。其中R、R1、R2、X、m、n和p如本文所述。更具体地，本发明的化合物是H3受体的调节剂，因此在制药剂中特别有用，尤其是在治疗和/或预防由H3受体调节的各种疾病，包括与中枢神经系统相关的疾病。此外，本发明还揭示了制备式(I)的取代N-烷基和N-酰基四氢异喹啉衍生物及其中间体的方法。
• Novel compounds
  申请人：——

  公开号：US20040235821A1

  公开（公告）日：2004-11-25

  The invention relates to thiophene carboxamides of formula (I), wherein R 1 , R 2 , R 3 , A, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. 1

  该发明涉及式(I)的噻吩羧酰胺，其中R1、R2、R3、A、n和X如规范中所定义，以及用于其制备的过程和中间体，包含它们的制药组合物以及它们在治疗中的使用。1